sutthirat sutthisumdang EF Hutton started coverage of NRx Pharmaceuticals ( NASDAQ: NRXP ) with a buy rating, calling it “two companies in one" aimed at addressing the nation's suicide crisis. The investment firm highlighted the company’s drug NRX-101, which it says has been shown to rapidly.
Back to Health Page
